SAB Biotherapeutics, Inc. (SABS) financial statements (2022 and earlier)

Company profile

Business Address 2100 EAST 54TH STREET NORTH
SIOUX FALLS, SD 57104
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments33,20785
Cash and cash equivalents33,20785
Restricted cash and investments6,338 
Prepaid expense8652
Other undisclosed current assets8,011 
Total current assets:48,42087
Noncurrent Assets
Finance lease, right-of-use asset4,019 
Operating lease, right-of-use asset2,615 
Property, plant and equipment24,314 
Deferred costs 235
Total noncurrent assets:30,949235
TOTAL ASSETS:79,369322
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,149156
Accounts payable4,459 
Accrued liabilities463156
Employee-related liabilities1,227 
Deferred revenue100 
Debt186 
Due to related parties 150
Other undisclosed current liabilities18,248 
Total current liabilities:24,684306
Noncurrent Liabilities
Long-term debt and lease obligation5,416 
Finance lease, liability3,762 
Operating lease, liability1,653 
Liabilities, other than long-term debt10,720 
Derivative instruments and hedges, liabilities10,720 
Total noncurrent liabilities:16,136 
Total liabilities:40,819306
Stockholders' equity
Stockholders' equity attributable to parent38,55016
Common stock40
Additional paid in capital67,67525
Accumulated deficit(29,129)(9)
Total stockholders' equity:38,55016
TOTAL LIABILITIES AND EQUITY:79,369322

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Revenues60,876 
Gross profit:60,876 
Operating expenses(74,269) 
Operating loss:(13,393) 
Nonoperating income
(Other Nonoperating income)
5 
Interest and debt expense371 
Loss from continuing operations before equity method investments, income taxes:(13,017) 
Other undisclosed loss from continuing operations before income taxes(4,128) 
Net loss available to common stockholders, diluted:(17,145) 

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss:(17,145) 
Comprehensive loss, net of tax, attributable to parent:(17,145) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: